Quoin Pharmaceuticals (QNRX) has launched the “NETHERTON NOW” campaign to shed light on the profound and poorly understood impacts of Netherton ...

Quoin Pharmaceuticals Ltd. (QNRX), a specialty pharmaceutical company currently valued at $2.42 million, announced today the initiation of the "NETHERTON NOW" campaign aimed at increasing awareness of ...

The recent 13% drop in Quoin Pharmaceuticals, Ltd.'s (NASDAQ:QNRX) stock could come as a blow to insiders who purchased US$580.9k worth of stock at an average buy price of US$0.48 over the past 12 ...

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) and keeping the price target at ...

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead ...

In a turbulent market environment, QNRX stock has reached a new 52-week low, trading at just $0.42. According to InvestingPro data, while the company maintains a FAIR financial health score and holds ...

(RTTNews) - Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Thursday, announced additional clinical data supporting the efficacy of its investigational ...

Quoin Pharmaceuticals Ltd (QNRX) experienced notable stock volatility following its Q4 2023 earnings call, as the company detailed its financial performance, strategic developments, and future ...

Quoin Pharmaceuticals has announced new clinical data indicating the need for ongoing treatment with QRX003 for patients with Netherton Syndrome, as all positive effects observed during a 12-week ...